If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) but wondered what that warning actually means in practical terms. Building on decades of pharmacovigilance research, this page explains the specific clinical signals that warrant closer monitoring and how doctors assess individual risk.
Building on the legacy of general health information, the focus now narrows to the specific risks associated with Tysabri (natalizumab). Tysabri is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri highlighting this risk, and the drug is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can include a range of neurological symptoms. Healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that PML is an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate the timeline between exposure and documented harm, with PML occurring after varying durations of therapy.
The mechanistic pathway linking Tysabri to PML involves the drug's pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain. This immunosuppressive effect can lead to reactivation of latent JCV, which is normally controlled by the immune system. The resulting viral infection of oligodendrocytes in the brain causes demyelination and the clinical syndrome of PML. The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning and the TOUCH Prescribing Program. The boxed warning clearly states that Tysabri increases the risk of PML and identifies the known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program restricts distribution to ensure that prescribers and patients are educated about the risks and that monitoring is performed. However, despite these warnings, PML continues to occur in treated patients, raising questions about the effectiveness of risk mitigation strategies. For affected patients, causation-related considerations are complex. The presence of anti-JCV antibodies, duration of therapy, and prior immunosuppressant use are established risk factors that can help establish a causal link between Tysabri and PML in individual cases. The timeline between exposure and harm is variable, with PML reported after as few as eight doses or after several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the need for ongoing vigilance and prompt evaluation of any new neurological symptoms in Tysabri-treated patients.
In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The FDA has issued a boxed warning and implemented a restricted distribution program to mitigate this risk. However, PML continues to occur, and patients and healthcare providers must remain vigilant for early signs of the disease. The mechanistic link between Tysabri and PML is understood through the drug's immunosuppressive effects, and risk factors such as anti-JCV antibodies, treatment duration, and prior immunosuppressant use are critical for assessing individual patient risk. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has issued a boxed warning for Tysabri (natalizumab) highlighting the increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. The drug is available only through a restricted distribution program called the TOUCH Prescribing Program to ensure prescribers and patients are educated about the risks and that monitoring is performed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain. This immunosuppressive effect can lead to reactivation of latent JC virus, which is normally controlled by the immune system. The resulting viral infection of oligodendrocytes in the brain causes demyelination and the clinical syndrome of PML.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.